School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China; Department of Radiology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, China.
Department of Nuclear Medicine, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510655, China.
Clin Radiol. 2019 Apr;74(4):278-286. doi: 10.1016/j.crad.2018.10.015. Epub 2019 Jan 25.
To evaluate the association between volume ratio of the mucus pool and tumour response to neoadjuvant therapy in patients with mucinous rectal adenocarcinoma (MC).
The volume of the mucus pool and whole tumour on pre-therapeutic T2-weighted magnetic resonance imaging (MRI) of 79 patients was measured using semi-automated software. Mucus pool volume, whole tumour volume, and volume ratio of the mucus pool were compared to tumour response and tumour and lymph node downstaging after neoadjuvant therapy using receiver operating characteristic curve (ROC) and multivariate logistic regression analysis.
After preoperative neoadjuvant therapy of rectal MC, the rate of pathological complete response, tumour downstaging, tumour response, and lymph node downstaging were 9%, 48%, 39% and 58%, respectively. Tumour downstaging more frequently occurred in patients with a mucus pool volume ratio of at least 68.3% (area under the ROC curve [AUC], 0.793 with 95% confidence interval [CI]: 0.693-0.893), and at least 62.1% for identifying those with a higher tumour response with an AUC of 0.739 (95% CI: 0.630-0.847).
A higher volume ratio of mucus pool in patients with MC may be related to more tumour downstaging and therapy response, and therefore, could serve as an independent imaging biomarker for predicting tumour response to neoadjuvant therapy.
评估黏液池体积比与直肠黏液腺癌(MC)患者新辅助治疗后肿瘤反应之间的关系。
对 79 例患者术前 T2 加权磁共振成像(MRI)的黏液池和整个肿瘤体积使用半自动软件进行测量。使用受试者工作特征曲线(ROC)和多变量逻辑回归分析比较黏液池体积、整个肿瘤体积和黏液池体积比与新辅助治疗后的肿瘤反应和肿瘤及淋巴结降期。
直肠 MC 患者术前新辅助治疗后,病理完全缓解率、肿瘤降期率、肿瘤反应率和淋巴结降期率分别为 9%、48%、39%和 58%。黏液池体积比至少为 68.3%的患者肿瘤降期更常见(ROC 曲线下面积[AUC]为 0.793,95%置信区间[CI]:0.693-0.893),至少为 62.1%的患者可识别出具有更高肿瘤反应的患者,AUC 为 0.739(95%CI:0.630-0.847)。
MC 患者黏液池体积比更高可能与更多的肿瘤降期和治疗反应相关,因此可作为预测新辅助治疗后肿瘤反应的独立影像学生物标志物。